Gastric cancer is closely associated with mutations in p53 and Epidermal Growth Factor Receptor (EGFR), disrupting key cellular regulatory functions. Quinazoline derivatives have demonstrated anticancer activity, yet their molecular interactions with p53 and EGFR remain unexplored. This study investigates these interactions through molecular docking, followed by structural optimization to enhance binding affinity. Stability was further assessed using molecular dynamics (MD) simulations, and pharmacokinetic properties were evaluated via ADMET analysis. The optimized derivatives Q-2, Q-4, and Q-9 showed strong binding affinities to p53 (Val147) with energies of −8.3120, −8.1330, and −8.1240 kcal/mol, and to EGFR (Asp831) with energies of −8.7090, −8.7800, and −9.1060 kcal/mol. MD simulations revealed that Q-2–p53 and Q-9–EGFR complexes maintained high structural stability, while ADMET predictions confirmed favorable pharmacokinetics. These findings indicate that Q-2 and Q-9, as optimized forms of known quinazoline scaffolds, have strong potential as lead compounds for targeted gastric cancer therapy.
Kusumaningrum AP, Astuti E, Pranowo HD. Molecular docking study and molecular dynamics simulation of quinazoline derivatives targeting p53 and EGFR proteins as anti gastric cancer. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2026.259319
1. Tan N, Wu H, Cao M, Yang F, Yan X, He S, et al. Global, regional, and national burden of early-onset gastric cancer. Cancer Biol Med. 2024;21(8):667–78. doi: https://doi.org/10.20892/j.issn.2095-3941.2024.0159
2. Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22(2):127–44. doi: https://doi.org/10.1038/s41573-022-00571-8
3. Liu Z, Liu L, Li M, Wang Z, Feng L, Zhang Q, et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology. 2011;43(3):234–8. doi: https://doi.org/10.1097/PAT.0b013e328344e61b
4. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14(1):1–3. doi: https://doi.org/10.1007/BF00690207
5. Hu X, Tang S, Yang F, Zheng P, Xu S, Pan Q, et al. Design, synthesis, and antitumor activity of olmutinib derivatives containing acrylamide moiety. Molecules. 2021;26:3041. doi: https://doi.org/10.3390/molecules26103041
6. Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20(10):815–34. doi: https://doi.org/10.2174/1568026620666200303123102
7. Elzahabi HSA, Nafie MS, Osman D, Elghazawy NH, Soliman DH, El-Helby AAH, et al. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. Eur J Med Chem. 2021;222:113609. doi: https://doi.org/10.1016/j.ejmech.2021.113609
8. Wei XW, Yuan JM, Huang WY, Chen NY, Li XJ, Pan CX, et al. 2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation, and in vivo effective anticancer agents. Eur J Med Chem. 2020;186:1–6.
9. Ghorab MM, Soliman AM, El-Adl K, Hanafy NS. New quinazoline sulfonamide derivatives as potential anticancer agents: identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity. Bioorg Chem. 2023;140:1–5. doi: https://doi.org/10.1016/j.bioorg.2023.106791
10. Abdelazeem AH, Alqahtani AM, Arab HH, Gouda AM, Safi El-din AG. Novel benzo4,5thiazolo2,3-C1,2,4triazoles: design, synthesis, anticancer evaluation, kinase profiling and molecular docking study. J Mol Struct. 2021;1246:131138. doi: https://doi.org/10.1016/j.molstruc.2021.131138
11. Singh RK. Key heterocyclic cores for smart anticancer drug—Design Part I. Singapore: Bentham Science Publishers Ptd. Ltd; 2022. pp. 167–8.
12. Rani M, Sharma AK, Chouhan RS, Sur S, Mansuri R, Singh RK. Natural flavonoid pectolinarin computationally targeted as a promising drug candidate against SARS-CoV-2. Curr Res Struct Biol. 2024;7:100120. doi: https://doi.org/10.1016/j.crstbi.2023.100120
13. Rani M, Sharma AK, Nischal A, Khattri S, Sahoo GC, Singh RK. Molecular Dynamics (MD) simulation of GPR87-LPA binding: therapeutic implications for targeted cancer treatment. Anticancer Agents MedChem. 2025;25(17):1342–58. doi: https://doi.org/10.2174/0118715206374428250403103159
14. Abdur S, Akira R. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach. Protein J. 2013;32(32):68–74. doi: https://doi.org/10.1007/s10930-012-9458-x
15. Baud MGJ, Bauer MR, Verduci L, Dingler FA, Patel KJ, Horil Roy D, et al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur J Med Chem. 2018;152:101–14. doi: https://doi.org/10.1016/j.ejmech.2018.04.035
16. Garg S, Singh J, Verma SR. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics. J Mol Model. 2023;29(2):1–1. doi: https://doi.org/10.1007/s00894-023-05454-2
17. Alsaid MS, Al-Mishari AA, Soliman AM, Ragab FA, Ghorab MM. Discovery of Benzo[g] quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. Eur J Med Chem. 2017;141:84–91.
18. Bibi S, Urrehaman S, Akram M, Amin R, Majeed H, Khan SR, Younis S, et al. Molecular docking and DFT study of antiproliferative ribofuranose nucleoside derivatives targeting EGFR and VEGFR2 in cancer cells. Comput Biol Chem. 2024;113:108187. doi: https://doi.org/10.1016/j.compbiolchem.2024.108187
19. Hunter CA, Sanders JKM. The Nature of π-π Interactions. J Am Chem Soc. 1990;112(14):5525–34. doi: https://doi.org/10.1021/ja00170a016
20. Tobajas-Curiel G, Sun Q, Sanders JKM, Ballester P, Hunter CA. Substituent effects on aromatic interactions in water. Chem Sci. 2023;14(23):6226–36. doi: https://doi.org/10.1039/d3sc01027a
21. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337–41. doi: https://doi.org/10.1016/j.ddtec.2004.11.007
22. Elsanhoury R, Alasmari A, Parupathi P, Jumaa M, Al-Fayoumi S, Kumar A, et al. AI & experimental-based discovery and preclinical IND-enabling studies of selective BMX inhibitors for development of cancer therapeutics. Int J Pharm. 2023;645:1–3. doi: https://doi.org/10.1016/j.ijpharm.2023.123384
23. Pérez MAC, Sanz MB, Torres LR, Ávalos RG, González MP, Díaz HG. A topological sub-structural approach for predicting human intestinal absorption of drugs. Eur J Med Chem. 2004;39(11):905–16. doi: https://doi.org/10.1016/j.ejmech.2004.06.012
24. Vilar M, Chakrabarti S, Costanzi S. Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model. 2010;28(8):899–903. doi: https://doi.org/10.1016/j.jmgm.2010.03.010
25. Ahmad H, Khan G, Serdaro?lu I. Physicochemical properties, drug likeness, ADMET, DFT studies, and in vitro antioxidant activity of oxindole derivatives. Comput Biol Chem. 2023;104:1–3. doi: https://doi.org/10.1016/j.compbiolchem.2023.107861
26. Abdullahi SH, Moin AT, Uzairu A, Umar AB, Ibrahim MT, Usman MT, et al. Molecular docking studies of some benzoxazole and benzothiazole derivatives as VEGFR-2 target inhibitors: in silico design, MD simulation, pharmacokinetics, and DFT studies. Intell Pharm J. 2023;2(2):232–50. doi: https://doi.org/10.1016/j.ipha.2023.11.010
27. Mishra A, Rathore AS. RNA-dependent RNA polymerase (RdRp) as a drug target for SARS-CoV-2. J Biomol Struct Dyn. 2022;40(13):6039–51. doi: https://doi.org/10.1080/07391102.2021.1875886
28. Mrozek-Wilczkiewicz A, Kuczak M, Malarz K, Cie?lik W, Spaczy?ska E, Musiol R. The synthesis and anticancer activity of 2-styrylquinoline derivatives. A p53-independent mechanism of action. Eur J Med Chem. 2019;177:338–49. doi: https://doi.org/10.1016/j.ejmech.2019.05.061
29. Yang Y, Si Z, Cai D, Teng X, Li G, Wang Z, et al. High-hydrophobic-CF3 groups within PTFPMS membrane for enhancing the furfural pervaporation performance. Sep Purif Technol. 2020;235:1–8. doi: https://doi.org/10.1016/j.seppur.2019.116144
30. Salentin S, Haupt VJ, Daminelli S, Schroeder M. Polypharmacology rescored: protein-ligand interaction profiles for remote binding site similarity assessment. Prog Biophys Mol Biol. 2014;116(2–3):174–86. doi: https://doi.org/10.1016/j.pbiomolbio.2014.05.006
31. Majumder R, Mandal M. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach. J Biomol Struct Dyn. 2022;40(2):696–711. doi: https://doi.org/10.1080/07391102.2020.1817787
Year
Month